“The Ministry of Health of the Russian Federation has conducted an examination of preclinical studies of the drug for the treatment of COVID-19, developed at the FMBA of Russia.
Based on the results of the examination, permission was issued to conduct the first phase of clinical trials, ”the ministry said in a statement.
As noted by the head of the FMBA, Veronika Skvortsova, if clinical trials prove its effectiveness, "this will be the first safe, effective, direct-acting antiviral drug that has no analogues in the world."
Earlier, Skvortsova said that FMBA has developed and patented two unique drugs for coronavirus that have no analogues.